Latest News and Press Releases
Want to stay updated on the latest news?
-
PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study PRAX-114 Phase 2/3 monotherapy MDD Aria Study completed; topline results...
-
BOSTON, April 01, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
-
VANCOUVER, British Columbia, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Franciosi Consulting Ltd. will be performing structure activity analyses of published beta-adrenergic receptor antagonists (a.k.a. beta...
-
BOSTON, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
-
Initiated PRAX-114 Phase 2 Acapella Study for adjunctive treatment of Major Depressive Disorder (MDD) Enrollment on track for 1H22 topline results in PRAX-114 Phase 2/3 Aria Study for monotherapy...
-
Expands pipeline with new indications for PRAX-114 and PRAX-944 PRAX-114 Phase 2 trial for treatment of post-traumatic stress disorder to initiate in 2H21 PRAX-114 Phase 2 trial for...
-
BURLINGAME, Calif., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Cala Health, Inc, a neuromodulation platform company developing wearable therapies for chronic disease, today announced that the first patients...